CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients

• Principais autores: Teerapat Majam (Autor), Chonlaphat Sukasem (Autor), Thanyanan Reungwetwattana (Autor), Phichai Chansriwong (Autor), Chalirmporn Atasilp (Autor), Narumol Trachu (Autor), Thanaporn Thamrongjirapat (Autor), Rattanaporn Sukprasong (Autor), Jennis Meanwatthana (Autor)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2023-11-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background: Osimertinib has shown greater efficacy than standard epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and fewer grade 3 or higher adverse drug reactions (ADRs) in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (...